Live Earnings Conference Call: Xenon Pharmaceuticals will host a live Q2 2025 earnings call on August 11, 2025 at 4:30PM ET. Follow this link to get details and listen to Xenon Pharmaceuticals' Q2 2025 earnings call when it goes live. Get details. Xenon Pharmaceuticals (XENE) Competitors $33.43 -0.20 (-0.59%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$33.45 +0.02 (+0.06%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, RYTM, and NUVLShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Rhythm Pharmaceuticals Nuvalent BridgeBio Pharma (NASDAQ:BBIO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability. Do analysts recommend BBIO or XENE? BridgeBio Pharma currently has a consensus target price of $61.35, suggesting a potential upside of 31.72%. Xenon Pharmaceuticals has a consensus target price of $54.33, suggesting a potential upside of 62.53%. Given Xenon Pharmaceuticals' higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, BBIO or XENE? BridgeBio Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Does the media prefer BBIO or XENE? In the previous week, BridgeBio Pharma had 25 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 38 mentions for BridgeBio Pharma and 13 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.82 beat BridgeBio Pharma's score of 0.49 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 11 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, BBIO or XENE? Xenon Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M40.13-$535.76M-$4.09-11.39Xenon Pharmaceuticals$9.43M272.01-$234.33M-$3.23-10.35 Do insiders & institutionals have more ownership in BBIO or XENE? 99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is BBIO or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% Xenon Pharmaceuticals N/A -32.44%-30.84% SummaryXenon Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.57B$2.99B$5.48B$9.71BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-10.3517.3230.1124.70Price / Sales272.01325.38454.41110.27Price / CashN/A40.7324.8428.01Price / Book3.388.888.515.76Net Income-$234.33M-$54.75M$3.27B$267.05M7 Day Performance0.81%-2.07%4.59%3.13%1 Month Performance3.79%1.81%0.89%1.27%1 Year Performance-15.79%8.71%36.22%22.83% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.0549 of 5 stars$33.43-0.6%$54.33+62.5%-15.8%$2.57B$9.43M-10.35210BBIOBridgeBio Pharma4.7329 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M-13.53400Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5508 of 5 stars$105.47+0.3%$109.00+3.3%+365.4%$8.95B$42.28M-52.7430Positive NewsEarnings ReportBPMCBlueprint Medicines0.6339 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.143 of 5 stars$11.51+1.8%$16.50+43.4%+3.3%$7.69B$29.05M-46.04860Positive NewsGRFSGrifols3.249 of 5 stars$10.72-0.6%$10.30-3.9%+47.9%$7.41B$7.81B9.1623,822LEGNLegend Biotech3.8187 of 5 stars$38.45-0.9%$73.33+90.7%-33.8%$7.13B$627.24M-65.172,609Positive NewsELANElanco Animal Health3.3218 of 5 stars$14.07+2.1%$16.17+14.9%+27.4%$6.85B$4.44B19.029,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.3509 of 5 stars$37.18+1.5%$68.91+85.3%-18.4%$6.82B$11.58M-9.30250Earnings ReportAnalyst RevisionRYTMRhythm Pharmaceuticals3.996 of 5 stars$90.24+2.2%$91.93+1.9%+103.2%$5.62B$130.13M-32.11140Earnings ReportAnalyst RevisionNUVLNuvalent3.1149 of 5 stars$78.35+0.8%$119.60+52.6%+5.9%$5.58BN/A-17.8540Earnings ReportUpcoming EarningsInsider TradeAnalyst Revision Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale